Human basal cell cancer (BCC) has unique growth characteristics with virtual inability to metastasize. We investigated clonality and genetic progression using p53 mutations as marker. Sampling was done through microdissection of frozen immunohistochemically stained 16 mm slices of tumors. From 11 BCC tumors 78 samples were analysed. Direct DNA sequencing of exons 5 ± 8 was performed, haplotypes were determined after cloning of p53 exons and loss of heterozygosity (LOH) ascertained by microsatellite analysis. All tumors had p53 mutations and in a majority both p53 alleles were aected, commonly through missense mutations. Microdissection of small parts (50 ± 100 cells) of individual tumors showed BCC to be composed of a dominant cell clone and prone to genetic progression with appearance of subclones with a second and even third p53 mutation. Samples from normal immunohistochemically negative epidermis always showed wild type sequence, except for a case of previously unknown germline p53 mutation. Our analysis also included p53 immunoreactive patches i.e. morphologically normal epidermis with a compact pattern of p53 immunoreactivity. Mutations within those were never the same as in the adjacent BCC. This detailed study of only one gene thus uncovered a remarkable heterogeneity within a tumor category famous for its benign clinical behavior.
Introduction
p53 is the most commonly mutated gene in human cancer (Harris, 1995; Hollstein et al., 1996; Levine et al., 1991) . The normal p53 protein has an important role in control of the cell cycle after DNA damage (Lane, 1992) . p53 is then known to rise in concentration which indirectly leads to a block at the restriction point of cells in late G1 of the cell cycle, allowing DNA repair to occur before replication, or in case of extensive DNA damage, induces apoptosis. p53 has also been suggested to control the euploidy of cells (Cross et al., 1996) . If p53 is inactivated, either through mutations or deletions, these functions will not be sustained. Mutations in skin cancer often display a u.v. signature, i.e. CC to TT or C to T transitions at dipyrimidine sites (Brash et al., 1991 (Brash et al., , 1996 Kress et al., 1992) . Reported prevalence of p53 mutations in BCC diers from 10 ± 60% (Brash et al., 1991; Campbell et al., 1993; Kubo et al., 1994; Rady et al., 1992) , however the signi®cance of p53 gene mutations in BCC remains unsolved. Are p53 gene mutations essential for BCC development and growth or are they merely markers of clonally expanding tumor cells?
Clinically BCC appears as a slowly expanding locally malignant neoplasm with ultraviolet light as its major cause (Diey et al., 1979; Gallagher et al., 1995; Kricker et al., 1994) . A rare familiar form, the basal cell nevus syndrome (BCNS), exists in which patients develop multiple BCC:s at early age. The gene involved was recently cloned (Hahn et al., 1996; Johnson et al., 1996) . Due to the histologically multifocal appearance of the super®cial type of BCC, its clonal unicellular origin is debatable (Imayama et al., 1987; Madsen, 1965) . Although the tumor persists for a long time, progression is virtually unknown and BCC will almost never metastasize (von Domarus and Stevens, 1984) . Explanations could be that the tumor is dependent on a speci®c, dermal connective tissue stroma for its growth van Scott and Reinertson, 1961) and/or that its genetic stability is unusually solid.
In this study we have used a microdissection based technique for detailed examination of dierent parts of 11 individual tumors (Table 1) . Mutations and loss of heterozygosity (LOH) in the p53 gene were analysed and correlated to morphology. Our method permitted detailed insights in the biology of BCC. The multiplicity of ®ndings from a frozen moment in time allowed conclusions on previous events in an archeological style. We addressed two questions in particular. Is BCC of clonal origin? Does genetic progression occur?
Results
Altogether 78 samples, including surrounding normal tissue, from 11 excised tumors were collected. In 51 samples of tumor cells we found all BCC:s to have at least one p53 mutation. The 11 tumors contained 25 dierent mutations (20 missense, four nonsense and one intron mutation), but no`silent' mutation aecting the third base of a redundant codon. Almost all mutations occurred at evolutionarily conserved amino acids, only one case (U-4) showed a mutation in a nonconserved amino acid. Many of the mutations were found in the conserved II region of the core domain (127 ± 158), an area of the gene which has not been reported as a hot spot (Figure 1 ). In addition, mutations clustered around codons 173 ± 179 and 235 ± 250, previously described as hot spots (Ziegler et al., 1993) . 70% of the mutations were C to T transitions at dipyrimidine sites, including two CC to TT transitions, compatible with u.v. as a cause. LOH involving the p53 gene was found in four of 11 informative tumors. Two (U-5 and U-10) had consistent loss of one allele, whereas two (U-7 and U-11) had acquired LOH in only one sampled tumor area.
Single acquired point mutations were found in six of 10 p53 immunoreactive patches of morphologically normal epidermis. No patch had LOH. Patch mutations were never the same as in the adjacent BCC, but like in the tumor, they generally occurred as missense mutations at evolutionarily conserved amino acids. All 30 exon mutations found in tumors and patches coded for an altered protein. We never found an acquired mutation or LOH in samples from normal, p53 non-immunoreactive adjacent tissue.
All samples from U-5, including normal epidermis and subcutaneous tissue, contained a constitutional mutation in codon 235. The same mutation was also found in a peripheral blood sample obtained one year after excision of the examined tumor.
The set of samples from each BCC had at least one mutation in common. U-8 was the sole exception, since only one out of two specimens showed a mutation in the exons examined. Six BCC:s (U-6, U-7, U-8, U-9, U-10, U-11) showed progressive genetic changes, for example one common mutation in all samples with addition of a second mutation (or LOH) in parts of the same tumor. Two of these (U-10 and U-11) revealed mutation patterns indicating genetic progression in two dierent directions, i.e. a parental mutation(s) was accompanied by dierent secondary mutations in opposite areas within the same tumor. In U-11, from which 13 BCC samples were obtained, we found six dierent mutations. Two of these were ubiquitous, two were in dierent localized areas of the tumor, while two mutations were only found in single tumor samples. See Figures 2 and 3 .
A majority of the tumors (seven) had two point mutations in the p53 gene and two tumors showed more than two mutations. In six of the tumors mutations were situated closely enough to be subject to cloning of PCR fragments. In four BCC:s the mutations aected dierent alleles. In the remaining two, mutations were found on the same allele, however in one case (U-10) there was LOH and in the other case (U-11) additional third mutations were present. In this tumor (U-11) two dierent genotypes with (i) mutations of codon 130 and 158 and (ii) only mutation of codon 130 were found.
Our series of BCC showed a variable pattern of p53 immunoreactivity ranging from U-6 and U-7 where virtually all cells were positive to U-8 and U-9 with essentially no positive cells (Table 1) . U-9 turned out to have a p53 mutation leading to a stop codon and in U-8 only one of two sampled areas showed a single mutation with 30% mutation to wild type signal. The individual patterns could be described in three categories: (i) global dierences between areas; (ii) peripheral vs central distribution of positivity within individual nests; and (iii) scattered cell to cell variation vs uniform positivity within both central and peripheral parts of tumor nests. In spite of analysis of the staining pattern in these terms no obvious correlation existed between mutations and immunoreactivity (data not shown). (See Table 2 and Figure 2 for details).
Discussion
Basal cell cancer is an advantageous model of human cancer for its homogeneity, lack of tumor progression, de®ned exterior (u.v.) and inherited causes and ease of bioptic observation. Careful microdissection of many parts of individual tumors and direct DNA sequencing of p53 mutations as genetic markers has provided strong evidence for BCC:s unicellular origin. In (Hollstein et al., 1996) . Below the line are p53 mutations found in the Uppsala material of BCC (Hedrum et al., 1994; present study; unpublished) . Numbered codons represent codons where mutations in at least two dierent tumors have been found. Thick lines represent mutations involving adjacent codons, e.g. CC?TT in codons 157 ± 158 combination these methods have also disclosed unexpected progressive accumulation of lesions (point mutations and/or LOH) in the p53 gene. All examined tumors were informative, because they contained p53 mutations. Even where sets of genotypes were dierent, multiple samples from individual tumors had at least one mutation in common. This strongly indicates that basal cell cancers are derived from a single cell with a unique p53 mutation and that mutation is an early event. This is in contradiction to Table 2 Figure 3 Frozen sections of BCC (cases U-10 and U-11b) stained with antibody D-07 to p53, prior to microdissection. Top panels of ®gures show overview with arrows pointing to sampled areas. The other panels show higher magni®cation of sampled areas from left to right (corresponding to the arrows) with appropriate sample numbers. Note variations in immunoreactivity and morphology Table 2 Primary data for all 11 cases (U-1 to U-11) with sample numbers and type of microdissected tissue, followed by mutated codon Molecular pathology in basal cell cancer F Ponte Â n et al previously described ®eld cancerization in skin (Kanjilal et al., 1995) where multiple, unrelated p53 mutations were found within and around single tumors. Since no allowance was made in those reports for commonly present p53 mutated epidermal patches, these ®ndings probably depend on inadvertent inclusion of DNA from such patches. The absence of mutations in a few samples from the non-immunoreactive cases U-8 (#50) and U-9 (#70), where two tumor samples showed wild type sequence is still -TTC  CGC -TGC  GAG -AAG  CTC -TTC  CGC -TGC  CAG -TAG  GAG -AAG  CTC -TTC  CGA -TGA  GAG -AAG   CTC -TTC  CGC -TGC  GAG -AAG  CTC -TTC  CGC -TGC  GAG -AAG  CTC -TTC  CGA -TGA  GAG -AAG  CTC -TTC  CGA -TGA  GAG -AAG  CTC -TTC  CGA -TGA  GAG -AAG  CTC -TTC  CGC -TGC GAG -AAG Leu ± Phe (I) Arg ± Stop (I) Glu ± Lys (C) Leu ± Phe (I) Glu ± Lys (C) Leu ± Phe (I) Arg ± Gln (I) Glu ± Lys (C) Leu ± Phe (I) Glu ± Lys (C) Pro ± Leu (I) Leu ± Ser (I) IArg ± Cys (I) Glu ± Lys (C) Leu ± Ser (I) Arg ± Cys (I) Glu ± Stop (N) Glu ± Lys (C) Leu ± Ser (I) Arg ± Stop (I) Glu ± Lys (C) Leu ± Ser (I) Arg ± Cys (I) Glu ± Lys (C) Leu ± Ser (I) Arg ± Cys (I) Glu ± Lys C) Leu ± Ser (I) Arg ± Stop (I) Glu ± Lys (C) Leu ± Ser (I) Arg ± Stop (I) Glu ± Lys (C) Leu ± Ser (I) Arg ± Stop (I) Glu ± Lys (C) Leu ± Ser (I) Arg ± Cys (I) Glu ± Lys (C)   25%  35%  45%  10%  10%  30%  30%  35%   15%  10%  15%   20%  20%  50%  50%  15%  15%  65%  50%  50%  50%   50%  50%  40%  45%  40%  40%  50%  50%  50%  40%  50%  70%  35%  30%  30%  40%  30% A and B refers to on which allele the mutation resides, thus two mutations on the same allele is indicated by an A for both mutations, a mutation on the other allele is indicated by a B, nucleotide change and resulting amino acid change. I, C and N denotes residues identical, conserved or non-conserved among p53 proteins from diverse species. Z for residue involved in zink atom contact and D for denaturated structure in mutant (38). Mutation signal as determined from primary sequence curves and loss of heterozygosity (+) or presence of both p53 alleles (±) as determined by microsatellite analysis consistent with a unicellular origin, if our detected mutations in p53 occurred after transformation and not as an initial event. The alternative possibility of a primary mutation outside exons 5 ± 8 cannot be excluded. Our results con®rm those of (Madsen, 1965) , who after meticulous 3D reconstruction could show that apparently multifocal areas of any BCC, indeed, belonged to one tumor only. Mutations of p53 are obviously an early event in the natural history of BCC, but if they are present already at the point of time of malignant transformation is unsettled. This dicult problem may eventually be resolved by microdissection/sequencing of primordial cases of BCC with only a minute cluster of transformed cells in the basal epidermal layer. Our detailed maps have given an unprecedented view of events within a gene considered central in malignant human neoplasia. Below a calm surface of unremarkable non-informative morphology a lively panorama of genetic changes unfolds. The pattern of mutations and/or LOH indicate that a sequence of genetic`hits' aecting the p53 gene is typical. In ten of the 11 examined tumors both p53 alleles were altered. Inactivation of tumor suppressor genes is usually caused by an inactivating mutation in one allele and loss of the other (LOH) (Knudson, 1993) . This was a consistent ®nding in two tumors and in localized areas of two other tumors (U-7 and U-11), but in our other cases of BCC a mutation was followed by a second mutation rather than LOH. Cloning of PCR fragments from tumors with two mutations showed that the mutations were on dierent alleles. However, an apparently novel ®nding is that a mutation in one allele can also be followed by additional mutations in the same allele. Evidence for this was found in U-11 where cloning of PCR fragments (#26) revealed dierent clones, which either exhibited a single mutation (codon 130) or two mutations (codons 130 and 158). The ®ndings in U-10 also imply that a ®rst mutation (codon 177) was followed by second mutations (codons 142 and 152). Interestingly, in this tumor, independent branches of dierent sets of mutations spread in dierent directions. The selective advantage of such second (or even third) mutations within one allele is probably minute and might re¯ect the complex function of p53.
Inactivation through point mutations of both p53 alleles appears to be prevalent in BCC in contrast to the common ®nding of a mutation in one allele and loss of the second in other malignancies. Perhaps point mutations are favored in BCC, where deletions and other coarse genetic changes are rare. However, the consistent deletion of one allele (LOH) found in two tumors implicate that deletions, at least spanning the examined microsatellites, can also occur in BCC.
Mutations of p53 may be neutral markers of exposure to sunlight, causative or important for tumor progression. We do not favor the`neutral' alternative, mainly because our mutations almost invariably concerned nucleotides of considerable functional importance. Codons representing identical or evolutionarily conserved residues among p53 proteins may be important for normal protein function (Friend, 1994) . In our series, 22 of the 25 mutations in BCC were in identical or conserved regions (Table 2 ). Only two mutations in BCC corresponded to non-conserved residues, one of which turned out to be a germline mutation. Statistically predicted silent mutations were conspicuously absent.
The possible selection for more than one mutation in a tumor might be re¯ected in the slightly skewed pattern of mutated codons within the p53 gene found in the total Uppsala material (Hedrum et al., 1994; present study; unpublished) mutation patterns in BCC and cancers in general such a speculation, however, can only be substantiated through the careful investigation of a large number of BCC:s. No study has determined the true prevalence of p53 mutations in an unbiased sample of BCC cases (or any other human cancer). From this study we cannot draw ®rm conclusions on the incidence of p53 mutations in BCC in general. However, since all our BCC:s were selected without prior knowledge of their genotype and all of them still had mutations of the p53 gene, we conclude that BCC without any alteration of p53 must be rare. BCC may in fact be the human neoplasm where p53 mutations are most common. All samples from normal skin showed wild type p53, with the exception of U-5 where the mutation in codon 235 (Asn-Ser) was shared in all thirteen samples from tumor, patch, normal tissue (epidermis, mesenchymal and blood cells). We interpret the patient as a carrier of a germ-line mutation, which did not aect any known DNA binding site or hot spot. The patient's genotype was thus equivalent to what has been found in 50% of patients with the Li ± Fraumeni syndrome (Malkin, 1994) . However our patient, who was an ardent sailor and sun-lover, had no family history of cancers and was in good health at the age of 80. Evidently this heterozygous p53 mutation had not compromised life expectancy or caused any excessive cancer risk since it was merely accompanied by two BCC:s and one actinic keratosis at high age. The alternative interpretation that the altered codon 235 should be regarded as a polymorphism cannot be excluded. However, in that case it must be rare. It has not been found in normal tissue before and only few times in a variety of tumors (Hollstein et al., 1996) . Just as in Li ± Fraumeni the mutation did not cause cellular accumulation of p53 protein detectable by immunohistochemistry.
Findings in patches of morphologically normal p53 immunoreactive epidermis con®rmed previous observations (Ren et al., 1996a) . About two thirds had mutations of exons 5 ± 8, the strong compact immunoreactivity in the remainder remains unexplained. No genetic link was found between patches and even closely located BCC rendering it unlikely that the former are precursors of the latter. The dogma that BCC has no visible precursors was not shattered by our study.
Since the same mutations were found in samples of both immunoreactive and non-immunoreactive tumor cells from the same tumor, the mechanism which allows immunodetection of mutated p53 protein remains obscure. The apparent disparity of p53 immunohistochemistry in BCC stands in contrast to our observations with the same antibody, DO7, in squamous cell cancer and precursors as well as in p53 immunoreactive epidermal patches, where strong correlation existed between p53 immunoreactivity in undierentiated squamous cells and presence of p53 gene mutations (Ren, 1996; Ren et al., 1996a) .
Our`archaeological molecular pathology' has concentrated on one gene only, but given a surprisingly consistent and dynamic insight into genetic progression. We expect that this approach in the future will provide insight into mechanisms of tumor development, for example the role of the patched gene, responsible for the basal cell nevus syndrome (Hahn et al., 1996; Johnson et al., 1996) and probably also for spontaneous BCC.
Materials and methods

Tumor samples
Eleven basal cell cancers, eight from heavily sun-exposed areas of the skin, were studied. Six were of the super®cial and ®ve of the solid type. Six males and four females with age ranging from 49 ± 85 years (Table 1) were included. Immunohistochemistry, with an antibody to p53 (DO-7), was performed on 15 consecutively excised tumors and the nine most immunoreactive cases were used, along with two essentially immunonegative cases (U-8 and U-9). Tumors were excised at the Department of Plastic Surgery, University Hospital, Uppsala, Sweden, and sliced immediately after excision. One central slice was snap frozen and cryosectioned. Adjacent tumor slices were ®xed in buered formalin for routine staining and diagnosis.
Immumohistochemistry 16 mm cryosections were air dried at room temperature for 1 h. Immunohistochemistry was performed as described (Hedrum et al., 1994) . DO-7 (Dako, code M7001) was used as primary (dilution 1 : 200, incubation 30 min) and biotinylated rabbit anti-mouse (Dako, code E354) as secondary antibody (dilution 1 : 200, incubation 30 min). the immunoreaction was visualized by avidin/biotin complex (DAKO, code K355) using diaminobenzidine (DAB) as a chromogen. Mayer's hematoxylin was used for counterstaining. Immunohistochemical staining with DO-7 was also performed on the adjacent, formalin ®xed and paran embedded tumor specimen.
Sample preparation
Microdissection from p53 immunostained cryosections (exempli®ed in Figure 3 ) and preparation for DNA analysis were performed as published (Hedrum et al., 1994) . By immunohistochemistry a number of previously described patches Ren et al., 1996b) of p53 immunoreactive morphologically normal keratinocytes were localized. Immunostained slides, immersed in water were microdissected, using a small scalpel (Alcon Ophthalmic knife 158), in the following order: Normal epidermis, p53 patches and multiple samples from each tumor. The amount of cells microdissected in each sample ranged from 50 ± 500. Fifty-one tumor samples, 12 samples from normal, adjacent epidermis, within one case addition of mesenchymal tissue and a blood sample, and 13 samples from patches were collected. After microdissection, the cells were transferred to tubes containing 50 ml 10 mM TrisHCl (pH 8.3) and 50 mM KCl and lysed by addition of 2 ml Proteinase K (20 mg/ml; Boehringer Mannheim, Germany) at 568C for 1 h. Proteinase K was heat inactivated (958C, 10 min) prior to PCR.
Oligonucleotides
Primers used for DNA ampli®cation were situated in intronic sequences covering exons 5 ± 8 of the p53 gene and parts of the HLA-DQB1 locus, respectively (Berg et al., 1995) . The polymorphic HLA locus was used to control patient identity, i.e. to exclude contamination between tumors. Oligonucleotides were synthesized and labeled (biotin/FITC) as described (Hedrum et al., 1994) .
Thermocycling PCR was performed as described (Berg et al., 1995) for ampli®cation of chromosomal DNA fragments. In brief, exons 5 ± 8 of the human p53 gene, and the HLA-DQB1 locus were ampli®ed in a multiplex/nested con®guration. The outer multiplex ampli®cation of exons 4 ± 9 and the HLA locus was performed in one tube using 14 primers for 30 cycles, using AmpliTaq 1 and Stoel Fragment AmpliTaq 1 polymerases (Perkin Elmer, Norwalk, CT). After dilution of the reaction mixture (25-fold for p53 exons 5, 7, 8 and for HLA and 100-fold for exon 6), the inner region speci®c ampli®cations were performed for exons 5 ± 8 (30 cycles). The PCRs were performed in a mixture (50 ml) containing sample (5 ml cell lysate or 0.5 ± 2 ml outer PCR mixture), 10 mM Tris-HCl (pH 8.3), 2.0 mM MgCl 2 , 50 mM KCl, 1 ml/l Tween 20, 0.2 mM dNTPs and 0.1 mM of each primer. The outer PCR contained 1.0 U of AmliTaq DNA polymerase and 2.0 U of Amplitaq DNA polymerase, Stoel Fragment (both from Perkin Elmer, CA). The inner PCRs contained 1.0 U of AmpliTaq DNA polymerase. The inner PCR mixture for exon 5 diered by the concentration of KCl (10 mM) and MgCl 2 (2.5 mM). The temperature cycles consisted of denaturation at 948C 0.5 min (988C 0.25 min for inner PCR exon 5), annealing at 508C for outer PCR, 638C for inner PCRs for 0.5 min and extension at 728C for 1 min. Each PCR was initiated by a 5 min denaturation at 948C (3 min 988C for inner PCR exon 5), and the ®nal cycle was followed by a 10 min extension at 728C. Perkin Elmer 9600 thermocycler was used for all ampli®cations.
Solid-phase sequencing
One of the inner primers for each fragment was labeled with biotin to facilitate direct solid-phase sequencing of PCR templates by use of paramagnetic beads (Dynabeads 1 M-280 Streptavidin, Dynal AS, Oslo, Norway) as solid support. The biotinylated amplicons were immobilized onto streptavidin-coated solid support and strand speci®c elution with 0.05 M NaOH produced a clean template for sequencing. Solid-phase sequencing was performed as published (Berg et al., 1995; Hultman et al., 1989) with automated laser¯uorescent analysis (ALF TM , Pharmacia Biotech AB, Uppsala, Sweden). The sequences were compared with wild type p53 sequence as exempli®ed in Figure 4 . DNA sequence alterations were con®rmed by a second run starting from lysed cells or from a new microdissection.
Loss of heterozygosity
Chromosomal DNA was analysed for loss of heterozygosity (LOH) using two polymorphic microsatellites, the (AAAAT)-repeat located in intron 1 (Futreal et al., 1992) and the (CA)-repeat located downstream of exon 11 (Jones and Nakamura, 1992) . The microsatellites were ampli®ed by a duplex single PCR (Ren et al., 1996a) with one primer in each pair labeled with biotin. The PCR was performed in a mixture (50 ml) containing 5 ml cell lysate, 10 mM TrisHCl (pH 8.3), 2.0 mM MgCl 2 , 50 mM KCl, 1 ml/l Tween 20, 0.2 mM dNTPs and 0.2 mM of each of the four primers and 1.0 U of AmpliTaq DNA polymerase. The reaction was run for 35 cycles. The PCR templates were puri®ed by use of streptavidin coated paramagnetic beads and denatured using 10 ml NaOH (0.1 M). The eluted strand was neutralized with 6 ml HCl (0.167 M) and mixed with 32 ml formamid (95%). 6 ml of this mixture were analysed with Fragment Manager TM (Pharmacia Biotech AB, Uppsala, Sweden). Sizer TM 50 ± 500 (Pharmacia Biotech) was used as standard. LOH was determined by comparing DNA peak ratios. Cells from adjacent, morphologically and immunohistochemically unremarkable epidermis were de®ned as normal in the LOH assay.
Cloning of PCR fragments
Samples containing more than one mutation in the same or adjacent exons were analysed for haplotypes by cloning using the pGEM 1 -T Vector cloning kit (Promega), according to the manufacturer's instructions. Fragments of interest were ampli®ed with the biotinylated primer replaced by non-labeled primer, ligated into the vector and plasmids were transformed into E. coli strain RR1D M15 (RuÈ ther, 1982) . Colonies were screened by blue/white selection. Single colonies containing inserts were ampli®ed by PCR and sequenced, using vector speci®c primers. An average of ten colonies per cloned product were sequenced. A sequence containing both mutations revealed that they were situated on the same allele, i.e. belonged to one haplotype. Only one mutation in each sequence revealed that they were situated on dierent alleles.
